Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Emasan AG, the investment arm of the Sandoz family, has sold a significant stake in Swiss pharmaceutical giant Novartis (SIX:NOVN), generating 2.6 billion Swiss francs ($2.90 billion).
The sale, conducted through an accelerated bookbuilding process, saw Emasan AG offload 26.5 million Novartis shares at 98.25 Swiss francs each. Goldman Sachs, acting as the bookrunner, confirmed the transaction on Wednesday.
This move marks a substantial capital realization for Emasan AG, highlighting a strategic shift in the investment portfolio of the Sandoz family. Novartis, a global leader in pharmaceuticals, has been a key holding for Emasan AG, making this divestment particularly notable for investors tracking the Swiss stock market.
The deal is expected to impact Novartis’s share performance, given the scale of the transaction. Market analysts are closely watching how this sell-off influences investor sentiment and Novartis’s future stock valuation.
This article was generated with AI assistance and reviewed by an editor.
